EGFR Transactivation in the Regulation of SMC Function

Abstract

Vascular smooth muscle cells (SMCs) are the principal cellular component of the normal artery and intimal lesions that develop in response to arterial injury. Several growth factors and their receptors participate in SMC activation, including the tyrosine kinase receptors for platelet‐derived growth factor (PDGF) and basic fibroblast growth factor as well as the G‐protein‐coupled receptors (GPCRs) for thrombin and angiotensin II. During the last couple of years, it has become evident that GPCRs transactivate receptor tyrosine kinases, particularly the epidermal growth factor receptor (EGFR). The EGFR is not well characterized in terms of its role in vascular biology, but recent findings indicate that GPCRs induce EGFR transactivation in cultured vascular SMCs, perhaps by intracellular and extracellular pathways. Studies from our laboratory as well as two other groups have demonstrated that EGFR transactivation by different GPCR agonists and in different cell types, including SMCs, is mediated by heparin‐binding EGF‐like growth factor (HB‐EGF). HB‐EGF‐dependent EGFR activation is blocked by heparin, a growth inhibitor of SMCs in vitro and in vivo. These data suggest that the EGFR may be important in the regulation of SMC function. The complexity of the GPCR‐EGFR crosstalk, involving several different cell surface molecules and an inside‐out signaling step, may provide novel targets for the control of SMC growth and intimal hyperplasia in the arterial injury response.

EGF receptor activation during allergic sensitization affects IL‐6‐induced T‐cell influx to airways in a rat model of asthma

“…The EGF receptor (EGFR) is involved in the regulation of cell differentiation and proliferation and in the pathogenesis of various diseases including epithelial tumors [1,2]. The importance of the EGFR axis in cancer has best been studied in breast malignancies.…”

Negative Action of Hepatocyte Growth Factor/c-Met System on Angiotensin II Signaling via Ligand-Dependent Epithelial Growth Factor Receptor Degradation Mechanism in Vascular Smooth Muscle Cells

“…As shown in Online Figure I (d and e), HGF reduced EGFR expression after endothelin-1 and transforming growth factor-␤ stimulation, which are both known to induce EGFR transactivation. 17 Ligand-dependent downregulation of EGFR by HGF would be a common mechanism under growth factor stimulation that induces EGFR transactivation.…”

Protease-Activated Receptor-1 Antagonist F 16618 Reduces Arterial Restenosis by Down-Regulation of Tumor Necrosis Factor α and Matrix Metalloproteinase 7 Expression, Migration, and Proliferation of Vascular Smooth Muscle Cells

“…To examine whether F 16618 was also able to inhibit cell migration, human aortic SMCs were stimulated by heparin binding-epidermal growth factor (HB-EGF) and monocyte chemoattractant protein-1 (MCP-1), both of which contribute to the promigratory effects of thrombin (Brandes et al, 2001;Kalmes et al, 2001). At 10 M, the PAR1 antagonist had no significant effect on basal migration in control jpet.aspetjournals.org medium, but it suppressed the promigratory action of MCP-1 and HB-EGF (Fig.…”